CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes.
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗已经彻底改变了晚期和转移性肾细胞癌患者的治疗格局。然而，许多患者未能获益或最终复发，这凸显了寻找新型免疫靶点以克服原发性和获得性耐药的必要性。本综述讨论了目前正在研究的2种策略：解除维持免疫抑制的抑制性刺激（“刹车”）以及启动免疫系统靶向肿瘤细胞（“油门”）。我们探讨了每一类新型免疫治疗，包括其背后的原理、支持性临床前和临床证据以及局限性。
Immunotherapy has revolutionized treatment for patients with advanced and metastatic renal cell carcinoma. Nevertheless, many patients do not benefit or eventually relapse, highlighting the need for novel immune targets to overcome primary and acquired resistance. This review discusses 2 strategies currently being investigated: disabling inhibitory stimuli that maintain immunosuppression ("brakes") and priming the immune system to target tumoral cells ("gas pedals").
We explore each class of novel immunotherapy, including the rationale behind it, supporting preclinical and clinical evidence, and limitations.
MEMBER ACCOUNT
登录成功会直接打开下一页。
